Comparative Pharmacology
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus LIGNOSPAN STANDARD.
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus LIGNOSPAN STANDARD.
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs LIGNOSPAN STANDARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isocaine hydrochloride (mepivacaine) is an amino amide local anesthetic that blocks sodium ion channels in nerve cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. Levonordefrin is a vasoconstrictor that acts on alpha-adrenergic receptors to cause local vasoconstriction, prolonging the anesthetic effect.
Lidocaine, the active ingredient, inhibits voltage-gated sodium channels, blocking the initiation and conduction of nerve impulses, leading to local anesthesia.
Adult dental infiltration or nerve block: 1-2 mL of 2% solution (20 mg/mL isocaine hydrochloride with levonordefrin 1:20,000) administered subcutaneously; maximum single dose 5 mL (100 mg isocaine hydrochloride); maximum total dose 7 mL per appointment.
2% lidocaine with 1:100,000 epinephrine: 1-5 mL (20-100 mg lidocaine) locally infiltrated; max 7 mg/kg lidocaine (up to 500 mg) per procedure. For nerve block: 1-30 mL depending on site. Epinephrine max 0.2 mg (20 mL of 1:100,000 solution) in healthy adults.
None Documented
None Documented
Terminal elimination half-life is approximately 2.1 hours; clinically, accumulation may occur with repeated doses in renal impairment.
Terminal elimination half-life is approximately 1.5–2 hours in adults. Prolonged in hepatic impairment or heart failure.
Renal excretion of metabolites, primarily 4-hydroxy-2,6-dimethylaniline glucuronide and sulfate conjugates; less than 5% excreted unchanged in urine.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Biliary/fecal excretion is minimal.
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor